Monitoring Agency Report for the quarter ended March 31, 2026.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Valiant Laboratories has filed its quarterly monitoring agency report for funds raised through a Rights Issue conducted in July-August 2025. The Rights Issue raised INR 8,146.88 Lakhs through 1,08,62,500 equity shares at INR 75 per share. India Ratings & Research, acting as the monitoring agency, confirms no deviation from the stated objects of the issue. The funds have been deployed as follows: INR 5,800.51 Lakhs for adjustment of promoter unsecured loans, INR 139.51 Lakhs for repayment of outstanding loans to promoter entity Dhanvallabh Ventures LLP, INR 180.38 Lakhs for capital expenditure (ongoing), and INR 1,956.48 Lakhs for general corporate purposes. An amount of INR 52.74 Lakhs remains deployed in a fixed deposit with HSBC Bank. The report has been reviewed by the Audit Committee and Board of Directors on May 14, 2026.
This is a routine compliance filing confirming proper utilization of Rights Issue proceeds with no red flags. The clean bill of health from the monitoring agency is positive for shareholders as it validates that funds were used as intended in the offer document.